Cytosorbents (NASDAQ:CTSO) CEO Phillip Chan Purchases 3,774 Shares of Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan bought 3,774 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were purchased at an average price of $6.00 per share, for a total transaction of $22,644.00. Following the purchase, the chief executive officer owned 100,996 shares in the company, valued at $605,976. This represents a 3.88% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Cytosorbents Price Performance

CTSO stock traded down $0.33 during trading on Wednesday, reaching $5.73. The company’s stock had a trading volume of 4,907 shares, compared to its average volume of 7,862. Cytosorbents Corporation has a 1 year low of $5.13 and a 1 year high of $20.40. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. The company has a market capitalization of $18.06 million, a P/E ratio of -0.99 and a beta of 1.34. The company’s fifty day moving average is $7.20 and its 200-day moving average is $9.83.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.73. Cytosorbents had a negative return on equity of 431.65% and a negative net margin of 48.94%.The firm had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million. On average, research analysts expect that Cytosorbents Corporation will post -4.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cytosorbents presently has an average rating of “Hold” and an average target price of $107.50.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.